Holmes, Sophie E. http://orcid.org/0000-0002-4929-1932
Scheinost, Dustin
Finnema, Sjoerd J.
Naganawa, Mika
Davis, Margaret T.
DellaGioia, Nicole
Nabulsi, Nabeel
Matuskey, David
Angarita, Gustavo A.
Pietrzak, Robert H.
Duman, Ronald S.
Sanacora, Gerard
Krystal, John H.
Carson, Richard E.
Esterlis, Irina
Article History
Received: 23 October 2018
Accepted: 18 March 2019
First Online: 4 April 2019
Competing Interests
: Dr. Krystal acknowledges the following relevant financial interests. He is a co-sponsor of a patent for the intranasal administration of ketamine for the treatment of depression that was licensed by Janssen Pharmaceuticals, the maker of s-ketamine. He has a patent related to the use of riluzole to treat anxiety disorders that was licensed by Biohaven Medical Sciences. He has stock or stock options in Biohaven Medical Sciences, ARett Pharmaceuticals, Blackthorn Therapeutics, and Luc Therapeutics. He consults broadly to the pharmaceutical industry, but his annual income over the past year did not exceed $5,000 for any organization. He receives over $5,000 in income from the Society of Biological Psychiatry for editing the journal Biological Psychiatry. He has fiduciary responsibility for the International College of Neuropsychopharmacology as president of this organization. The remaining authors declare no competing interests.